Biocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...

Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.

Fulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.

Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...

Biocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech ...

The court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...

Biocon and Mylan had appealed against the single judge order as restrictions were imposed on the use of clinical data in the package insert...

The proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...

This is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."

Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.

Biocon and Mylan are engaged in a court battle in India against Swiss biotech firm Roche over marketing restrictions imposed on their trast...

Mylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...

The counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

In 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.